Publications by authors named "N Mesgouez-Nebout"
Background: The standard of care for the treatment of locally advanced rectal cancer (LARC) results in an excellent local disease control but the metastasis rates remain high. PRODIGE 23 demonstrated improved disease-free survival (DFS) and metastasis-free survival (MFS) with total neoadjuvant therapy versus standard of care in this population. Long-term analysis of overall survival (OS) is reported here.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness of a combination treatment involving abiraterone acetate plus prednisone, prostate bed radiotherapy, and goserelin in men experiencing biochemical recurrence after prostatectomy, focusing on the potential role of circulating tumor cells (CTCs).
- Conducted as a phase 2 trial with 46 participants over a median follow-up of 47 months, the results reported a 3-year biochemical recurrence-free survival rate of 81.5% and an alternative rate of 95.6%.
- Common side effects included acute issues like pollakiuria during radiotherapy and long-term effects like urinary incontinence, while non-radiotherapy-related side effects included hot flashes and hypertension, with a CTC count ≥5 linked to
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
Clin Transl Radiat Oncol
January 2024
Purpose: High-risk (HR) prostate cancer patients usually receive high-dose radiotherapy (RT) using a two-phase sequential technique, but data on a simultaneous integrated boost (SIB) technique are lacking. We prospectively evaluated the long-term results of urinary (GU) and digestive (GI) toxicity and survival data for high-dose RT using a SIB technique in HR and very high-risk (VHR) prostate cancer.
Methods: Patients were treated using an SIB technique in 34 fractions, at a dose of 54.
Background: Intensity modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) has become the standard treatment for patients with high-risk prostate cancer. Two techniques of rotational IMRT are commonly used in this indication: Volumetric Modulated Arc Therapy (VMAT) and helical tomotherapy (HT). To the best of our knowledge, no study has compared their related costs and clinical effectiveness and/or toxicity in prostate cancer.
View Article and Find Full Text PDFNeoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
May 2021
Background: Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant chemotherapy before preoperative chemoradiotherapy could reduce the risk of distant recurrences.
Methods: We did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France.